Andrew Lee

BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK, United Kingdom

Poster(s):

• ((SLC-053)) (SLC-053) Risk of Venous Thrombosis With Thrombocytopenia Syndrome After Vaccination With AZD1222: A European VAC4EU Post-Authorisation Safety Study
  Tuesday, August 26, 2025

  12:15 PM - 1:15 PM ET

• ((A-349)) (A-349) Assessing the Association Between COVID-19 Vaccination and Thrombotic Thrombocytopenia Syndrome (ATTEST Study): Analyses of English Data, 2020–2022
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• ((A-356)) (A-356) Safety Profile of Vaxzevria® COVID-19 Vaccine in the COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER)
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• ((B-274)) (B-274) Leveraging Complementary Study Designs to Enhance Drug Safety Assessment in Pregnancy: Benefits and Limitations
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET